Reference : The risk of subsequent osteoporotic fractures is decreased in subjects experiencing f...
Scientific journals : Article
Human health sciences : General & internal medicine
http://hdl.handle.net/2268/228206
The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies
English
Kendler, D.L. [> >]
Chines, A. [> >]
Brandi, M.L. [> >]
Papapoulos [> >]
Lewiecki, E.M. [> >]
Reginster, Jean-Yves mailto [Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
Munoz Torres, M. [> >]
Wang, A. [> >]
Bone, H.G. [> >]
Jan-2019
Osteoporosis International
Springer
30
1
71-78
Yes (verified by ORBi)
International
0937-941X
1433-2965
Germany
[en] denosumab ; fracture ; osteoporosis ; subsequent fracture
[en] Summary: This post-hoc analysis queried whether women experiencing fracture on denosumab indicates inadequate treatment response or whether the risk of subsequent fracture remains low with continuing denosumab. Results showed that denosumab decreases the risk of subsequent fracture and fracture sustained while on denosumab is not necessarily indicative of inadequate treatment response.
Introduction: This analysis assessed whether a fracture sustained during denosumab therapy indicates inadequate treatment response and if the risk of a subsequent fracture decreases with continuing denosumab treatment.
Methods: In FREEDOM, a clinical trial to evaluate the efficacy and safety of denosumab, postmenopausal women with osteoporosis were randomized to placebo or denosumab for 3 years. In the 7-year FREEDOM Extension, all participants were allocated to receive denosumab. Here we compare subsequent osteoporotic fracture rates between denosumabtreated subjects during FREEDOM or the Extension and placebo-treated subjects in FREEDOM.
Results: During FREEDOM, 438 placebo- and 272 denosumab-treated subjects had an osteoporotic fracture. Exposure-adjusted subject incidence per 100 subject-years was lower for denosumab (6.7) vs placebo (10.1). Combining all subjects on denosumab from FREEDOM and the Extension for up to 10 years (combined denosumab), 794 (13.7%) had an osteoporotic fracture while on denosumab. Of these, one or more subsequent fractures occurred in 144 (18.1%) subjects, with an exposure-adjusted incidence of 5.8 per 100 subject-years, similar
to FREEDOM denosumab (6.7 per 100 subject-years) and lower than FREEDOM placebo (10.1 per 100 subjectyears). Adjusting for prior fracture, the risk of having a subsequent on-study osteoporotic fracture was lower in the combined denosumab group vs placebo (hazard ratio [95% CI]: 0.59 [0.43–0.81]; P = 0.0012).
Conclusions: These data demonstrate that denosumab decreases the risk of subsequent fracture and a fracture sustained while on denosumab is not necessarily indicative of inadequate treatment response.
http://hdl.handle.net/2268/228206
10.1007/s00198-018-4687-2

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab. Results from the FREEDOM and FREEDOM Extension studies..pdfPublisher postprint647.55 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.